NEWARK, Calif. — Depomed Inc. has acquired the United States rights to migraine medication Cambia (diclofenac potassium for oral solution) from Nautilus Neurosciences for $48.7 million.

Depomed said Tuesday that under the agreement it also may pay Nautilus up to an additional $5 million based on the achievement of certain annual net sales milestones.

A non-steroidal anti-inflammatory drug (NSAID), Cambia indicated for acute treatment of migraine attacks with or without aura in adults.

The powdered formulation of diclofenac potassium, dissolved in liquid, has a rapid onset and has demonstrated in clinical studies relief of the pain and associated symptoms of migraine, including nausea, sensitivity to light and sensitivity to sound, according to Depomed. The product was launched in 2010.

Depomed noted that Cambia expands its portfolio in pain and neurology, in particular bolstering the company’s position with neurologists.

"Cambia, our third product acquisition in 18 months, is a unique and fast-acting treatment for migraine with long-term growth potential that is a great fit in our pain and neurology-focused portfolio," commented Jim Schoeneck, president and chief executive officer of Depomed. "Some of the capital secured in October 2013 from the sale of our royalties in type 2 diabetes assets is being put to work in this product acquisition that leverages our current infrastructure. We will continue to actively seek products that complement our pain and neurology portfolio and position us for a strong growth trajectory in the coming years."